Cargando…

Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity

IMPORTANCE: No retrospective cohort study has assessed the effectiveness of semaglutide at doses used in randomized clinical trials to treat obesity (ie, 1.7 and 2.4 mg). OBJECTIVE: To study weight loss outcomes associated with semaglutide treatment at doses used in randomized clinical trials for pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghusn, Wissam, De la Rosa, Alan, Sacoto, Daniel, Cifuentes, Lizeth, Campos, Alejandro, Feris, Fauzi, Hurtado, Maria Daniela, Acosta, Andres
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486455/ https://www.ncbi.nlm.nih.gov/pubmed/36121652 http://dx.doi.org/10.1001/jamanetworkopen.2022.31982

Ejemplares similares

A comparison between weight loss outcomes with anti-obesity medications before and during Covid-19 pandemic at a tertiary weight management center
por: De la Rosa, Alan, et al.
Publicado: (2022)

1156: A COMPARISON BETWEEN REAL WORLD WEIGHT LOSS OUTCOMES WITH ANTI-OBESITY MEDICATIONS BEFORE AND DURING COVID-19 PANDEMIC
por: Rosa, Alan De la, et al.
Publicado: (2022)

Association Between Food Intake and Gastrointestinal Symptoms in Patients With Obesity
por: Ghusn, Wissam, et al.
Publicado: (2023)

Phenotype tailored lifestyle intervention on weight loss and cardiometabolic risk factors in adults with obesity: a single-centre, non-randomised, proof-of-concept study
por: Cifuentes, Lizeth, et al.
Publicado: (2023)

Weight-centric treatment of type 2 diabetes mellitus
por: Ghusn, Wissam, et al.
Publicado: (2022)

FRI078 Real-World Weight Loss Outcomes And Safety Of Tirzepatide, A Novel Dual GIP And GLP-1 Receptor Agonist
por: Fansa, Sima, et al.
Publicado: (2023)

Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review
por: Xie, Zeyu, et al.
Publicado: (2022)

Association between anxiety and eating behaviors in patients with obesity
por: Cifuentes, Lizeth, et al.
Publicado: (2022)

Weight-centric treatment of depression and chronic pain
por: Ghusn, Wissam, et al.
Publicado: (2022)

Association of Overweight, Obesity, and Recent Weight Loss With Colorectal Cancer Risk
por: Mandic, Marko, et al.
Publicado: (2023)

Semaglutide for the treatment of overweight and obesity: A review
por: Bergmann, Natasha Chidekel, et al.
Publicado: (2022)

Probability of 5% or Greater Weight Loss or BMI Reduction to Healthy Weight Among Adults With Overweight or Obesity
por: Kompaniyets, Lyudmyla, et al.
Publicado: (2023)

Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4)
por: Rubino, Domenica M, et al.
Publicado: (2021)

Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials
por: Gao, Xueqin, et al.
Publicado: (2022)

Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss
por: Wharton, Sean, et al.
Publicado: (2021)

Wegovy (semaglutide): a new weight loss drug for chronic weight management
por: Singh, Gurdeep, et al.
Publicado: (2022)

Preclinical Weight Loss Efficacy of AM833 in Combination With Semaglutide in Rodent Models of Obesity
por: John, Linu M, et al.
Publicado: (2021)

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
por: Garvey, W. Timothy, et al.
Publicado: (2022)

FRI077 Efficacy Of Anti-obesity Medications Among Breast Cancer Survivors Taking Aromatase Inhibitors
por: Fansa, Sima, et al.
Publicado: (2023)

Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis
por: Tan, Hanna Clementine, et al.
Publicado: (2022)

Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs
por: Carmina, Enrico, et al.
Publicado: (2023)

Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review
por: Deng, You, et al.
Publicado: (2022)

Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics
por: Lingvay, Ildiko, et al.
Publicado: (2022)

Weight control behaviors in overweight/obese U.S. adults with diagnosed hypertension and diabetes
por: Zhao, Guixiang, et al.
Publicado: (2009)

Gastric Sensory and Motor Functions and Energy Intake in Health and Obesity—Therapeutic Implications
por: Cifuentes, Lizeth, et al.
Publicado: (2021)

Comparison of neostigmine induced reversal of vecuronium in normal weight, overweight and obese female patients
por: Joshi, Shilpa Bhimasen, et al.
Publicado: (2015)

Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study
por: Wilding, John P H, et al.
Publicado: (2021)

Semaglutide 2.4 Mg for the Management of Overweight and Obesity: Systematic Literature Review and Meta-Analysis
por: Smith, Inger, et al.
Publicado: (2022)

Motivations for weight loss in adolescents with overweight and obesity: a systematic review
por: Silva, David Franciole Oliveira, et al.
Publicado: (2018)

Once-weekly Subcutaneous Semaglutide 2.4 mg Reduces Body Weight in Adults with Overweight or Obesity Regardless of Baseline Characteristics (STEP 1)
por: Kushner, Robert F, et al.
Publicado: (2021)

The Impact of Education on Weight Loss in Overweight and Obese Adults
por: Ostovan, Mohammad Ali, et al.
Publicado: (2013)

Genetic predictors of weight loss in overweight and obese subjects
por: Lamiquiz-Moneo, Itziar, et al.
Publicado: (2019)

Overweight and obesity: The efficacy of diets for weight maintenance after weight loss
por: Korczak, Dieter, et al.
Publicado: (2013)

Racial and Ethnic Disparities in Financial Barriers Among Overweight and Obese Adults Eligible for Semaglutide in the United States
por: Lu, Yuan, et al.
Publicado: (2022)

Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses
por: Kosiborod, Mikhail N., et al.
Publicado: (2022)

Clinically-Relevant Weight Loss is Achieved Independently of Early Weight Loss Response to Once-Weekly Subcutaneous Semaglutide 2.4 MG (STEP 4)
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Abstract 9: Once-weekly subcutaneous semaglutide 2.4 mg reduces body weight in adults with overweight or obesity regardless of baseline characteristics (STEP 1)
por: Suresh, Swaroop H, et al.
Publicado: (2022)

Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1)
por: Wilding, John P H, et al.
Publicado: (2021)

Correction to: Racial and Ethnic Disparities in Financial Barriers Among Overweight and Obese Adults Eligible for Semaglutide in the United States
Publicado: (2023)

Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials
por: Zhang, Rui, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vlmctu05j1jtvi03gr9jf2netg